Matthew Wein sold Metagenomi, Inc. ($MGX) shares on the open market four times in the last year, for a total of $1,832. His most recent sale occurred on March 5, 2026. These transactions rank 11,514th among 11,678 individual insiders, who averaged $8.6 million in sales and 6.4 transactions each. Wein made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | A | Stock Option (Right to Buy) | 68000 | $0.00 | 68,000.0000 | 37,546,751 | 9999.99% | 0.18% |
| April 1, 2026 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | A | Common Stock | 11000 | $0.00 | 125,549.0000 | 37,546,751 | 9.60% | 0.03% |
| March 5, 2026 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | S | Common Stock | 482 | $1.60 | 114,549.0000 | 37,546,751 | 0.42% | 0.00% |
| Dec. 5, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | S | Common Stock | 199 | $1.77 | 115,031.0000 | 37,546,751 | 0.17% | 0.00% |
| Sept. 5, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | S | Common Stock | 199 | $1.81 | 19,230.0000 | 1,870,923 | 1.02% | 0.01% |
| Dec. 1, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | A | Common Stock | 96000 | $1.60 | 115,230.0000 | 37,546,751 | 499.22% | 0.26% |
| June 6, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | S | Common Stock | 199 | $1.75 | 16,693.0000 | 1,870,923 | 1.18% | 0.01% |
| April 1, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | A | Stock Option (Right to Buy) | 22725 | $0.00 | 22,725.0000 | 1,870,923 | 9999.99% | 1.21% |
| April 1, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | A | Stock Option (Right to Buy) | 21875 | $0.00 | 21,875.0000 | 1,870,923 | 9999.99% | 1.17% |
| April 1, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | A | Common Stock | 3775 | $0.00 | 16,892.0000 | 1,870,923 | 28.78% | 0.20% |
| April 1, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | A | Common Stock | 3650 | $0.00 | 13,117.0000 | 1,870,923 | 38.55% | 0.20% |
| March 5, 2025 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | S | Common Stock | 930 | $1.87 | 9,467.0000 | 1,870,923 | 8.94% | 0.05% |
| April 1, 2024 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | A | Common Stock | 10397 | $0.00 | 10,397.0000 | 3,884,740 | 9999.99% | 0.27% |
| April 1, 2024 | Metagenomi Therapeutics, Inc. | $MGX | Wein Matthew | See Remarks | A | Stock Option (Right to Buy) | 43717 | $0.00 | 43,717.0000 | 3,884,740 | 9999.99% | 1.13% |